MedTrace Logo

Cannabidiol for the Treatment of Pelvic Pain in Endometriosis (DREAMLAND)

NCT05670353 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2025-04-02

No results posted yet for this study

Summary

The objective of this work is to conduct a randomized, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of cannabis extract in women with endometriosis who have already undergone hormonal contraceptive treatment and surgery without satisfactory response.

Conditions

  • Endometriosis
  • Pelvic Pain

Interventions

DRUG

Cannabis Derivatives

CBD 10 mg (up-titrated until 150mg or adverse effects) daily for 9 weeks

DRUG

Placebo

Placebo 10 mg (up-titrated until 150mg or adverse effects) daily for 9 weeks

DRUG

Hormonal Contraceptive Agents

All participants will be given hormonal contraceptive.

Sponsors & Collaborators

  • University of Sao Paulo

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-03
Primary Completion
2024-09-12
Completion
2024-11-20

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05670353 on ClinicalTrials.gov